Imron T. Aly is a trial lawyer who serves as lead counsel for clients on dozens of matters, and has first-chaired more than 10 trials. Imron is co-leader of Schiff Hardin’s Intellectual Property Group and co-chair of the firm's Hatch-Waxman and Biosimilars patent litigation team. His practice is focused on patent infringement litigation. He has litigated and tried patent infringement and other IP matters related to pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods, and financial trading systems. Clients and leading industry publications describe Imron as a prepared courtroom advocate whose “tenacity sets him apart,” who “stands out for his pure advocacy skills,” and “is an untiring advocate for his clients’ cause.”

Previous Experience

Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.

  • Experience

    • Fresenius Kabi USA, LLC v. FERA Pharmaceuticals, LLC (Successfully represented Fresenius Kabi USA, LLC in obtaining a rare preliminary injunction in federal district court. The injunction barred our client’s competitor from launching a generic version of its patented formulation of levothyroxine, an injectable thyroid hormone. The District Court for the District of New Jersey granted the injunction on the basis that our client was likely to win its patent lawsuit against its competitor.)
    • Vanda v. Lupin (Represent Lupin in iloperidone ANDA litigation)
    • Alcon v. Lupin (Represent Lupin in olopatadine ANDA litigation)
    • Horizon v. Lupin (Represent Lupin in naproxen/esomeprazole ANDA litigation)
    • BMS v. Lupin (Represent Lupin in apixaban ANDA litigation)
    • Sanofi v. Accord (Represent Accord in cabazitaxel ANDA litigation)
    • Forest Labs v. Hikma (Represented Hikma in trial for asenapine maleate ANDA litigation)
    • Cumberland Pharmaceuticals v. InnoPharma (Represented InnoPharma in acetylcysteine IV ANDA litigation)
    • Antares v. Medac (Represented Antares in medical device autoinjector patent litigation)
    • Cephalon v. Fresenius Kabi (Represented FK in arsenic trioxide ANDA litigation)
    • Onyx Pharma v. Fresenius Kabi (Represented FK in carfilzomib ANDA litigation)
    • Pfizer v. Fresenius Kabi (Represented FK in tigecycline 505(b)(2) trial)
    • Merck v. Fresenius Kabi (Represented FK in caspofungin 505(b)(2) trial)
    • Helsinn v. Fresenius Kabi (Represented FK in palonosetron ANDA litigation)
    • Celgene v. Fresenius Kabi (Represented FK in romidepsin ANDA litigation)
    • Mylan v. Fresenius Kabi (Represented FK in remifentanil ANDA litigation)
    • Shire Canada et al. v. Alkem Laboratories Ltd. (Represented Alkem in lanthanum carbonate ANDA litigation)
    • King Pharma Inc. and Meridian Medical Technologies Inc v. Teva Pharmaceuticals (Represented Teva in epinephrine injector ANDA litigation)
    • Aventis Pharma, S.A. and Sanofi-aventis Inc. v. Hospira Inc. (Represented Hospira including at trial in defending patent infringement claims for pharmaceutical involving docetaxel for cancer treatments)
    • Boehringer et al. v. Barr Laboratories (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving dipyradimole for stroke prevention)
    • Sepracor Inc. v. Barr Laboratories Inc. (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving levalbuterol for asthma treatments)
    • Maytag Corporation v. Whirlpool Corp. (Represented Whirlpool in defending patent infringement claims concerning mechanical dispensing systems technology)
    • Sears v. Bed Bath & Beyond (Represented Sears in patent case regarding electronic gift registry system)
    • Johnson Controls Inc. v. Lear Corp. (Represented Lear in patent case regarding remote control garage door opener circuitry and encryption)
    • Intellect Wireless v. Dell Inc. (Represented Dell in patent case involving cellular phone systems)
    • Nanogen Inc. v. Motorola Inc. (Represented Motorola in patent litigation concerning biomedical DNA hybridization microchip technology)
    • Computer Motion Inc. v. Intuitive Surgical Inc. (Represented Computer Motion in patent litigation concerning biomedical surgical robotics devices)
    • Oxford Gene Technology Ltd. v. Mergen Ltd. (Represented OGT in asserting patent infringement claims concerning DNA hybridization microarray biomedical technology)
    • Trading Technologies Intl. Inc. v. eSpeed Inc. (Representing eSpeed in defending patent infringement claims for a business-method patent concerning electronic futures trading)
    • International Game Technology Inc. v. Aristocrat Leisure Ltd. (Represented IGT in a patent litigation focusing on business-method patents for electronic funds management and ticketing systems)
  • Credentials


    • Georgetown University Law Center, J.D., 1999, magna cum laude
      Order of the Coif
      Georgetown Journal of Legal Ethics, Senior Articles Editor
    • Duke University, B.S.E., Biomedical Engineering, 1996, cum laude

    Bar Admissions

    • Illinois
    • Missouri
        • U.S. Patent and Trademark Office


          • Hon. Ann K. Covington, Missouri Supreme Court (1999-2000)

          Professional Memberships

          • Center for Biosimilars, Advisory Board, Member
          • Richard Linn American Inn of Court

          Teaching Appointments

          • Guest Lecturer, Patent Litigation, University of Michigan (2011, 2013)
        • Insights

          News Release

          Aly Joins Center for Biosimilars Advisory Board

          Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.

          In The News

          Strategic Considerations When Managing and Protecting Disruptive Technologies

          Managing Intellectual Property Innovation and Litigation Summit 2019

          San Francisco , Calif.
          News Release

          IAM Patent 1000 Ranks Firm, Attorneys in Patent Litigation

          Schiff Hardin LLP is proud to announce that the firm and three of its attorneys have been ranked in the eighth edition of IAM Patent 1000: The World’s Leading Patent Professionals.

          News Release

          Managing IP Recognizes Schiff Hardin Among IP Stars for Seventh Year

          Schiff Hardin is pleased to announce that the firm has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category, which includes dispute resolution work, litigation and enforcement, as well as Hatch-Waxman, International Trade Commission, and multinational litigation work.

          News Release

          Chambers USA 2019 Ranks 23 Attorneys, Four Practice Areas

          Schiff Hardin is pleased to announce that four practice areas and 23 attorneys have been recognized in the 2019 edition of Chambers USA, a leading legal industry ranking.

          News Release

          2019 Leading Lawyers Lists Recognize 95 Schiff Attorneys

          Schiff Hardin LLP is pleased to have 95 attorneys named to the 2019 Leading Lawyers list.

          News Release

          Super Lawyers Names 39 Schiff Attorneys to 2019 Illinois Super Lawyers, Rising Stars Lists

          Two partners were recognized among “best of the best” on 2019 Illinois Top Lists


          How Pharmaceutical Companies Can Navigate FDA During Shutdown

          As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).

          Other Publications

          • “Judge Allows Alternative Biologics Challenge,” Schiff Hardin Insight (Mar. 24, 2015)
          • “Myriad Faces Yet Another Patent Eligibility Battle In Return to the Federal Circuit,” Schiff Hardin Insight (Oct. 8, 2014)
          • “Encouraging Professionalism: The Magic Wand of the Patent Infringement Opinion,” Georgetown Journal of Legal Ethics (1999)
          • “Seller Beware: The Scope of the On Sale Bar after Pfaff v. Wells,” Texas Intellectual Property Law Journal (1999)

          Speeches & Presentations

          • “Strategic Considerations When Managing and Protecting Disruptive Technologies,” Managing Intellectual Property Innovation and Litigation Summit 2019, San Francisco , Calif. (Jun. 11, 2019)
          • “New Developments in U.S. Hatch-Waxman Litigation,” IP Leadership Forum, New Delhi, India (2014)
          • “Business Method Patents,” Software & Information Industry Association, Financial Information Services Division (2002)
        • Citizenship

          Pro Bono Activities

          Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.

          Civic and Charitable Memberships

          • Chicago Committee, Board Member
          • Metropolitan Tenants Organization, Former Board Member

        Product Liability and Mass Torts Blog

        FDA Issues Final Guidance on Biosimilars

        Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading


        Clients Rely on Aly and Patel as Strategic Advisers to Bring Generic Drugs to Market

        image description

        Aly and Patel are Strategic, Must-Have Advisers Who Bring Generic Drugs to Market Copy: Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace. MORE

        image description

        Pharma team scores rare preliminary injunction

        Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation. MORE